Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles

  • 0Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania.

|

|

Summary

This summary is machine-generated.

Androgen deprivation increases STEAP1 and STEAP2 in prostate cancer cells. STEAP1 is selectively packaged into extracellular vesicles, regardless of androgen receptor status, offering potential therapeutic insights.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biochemistry

Background

  • Six-transmembrane epithelial antigen of the prostate (STEAP) metalloreductases (STEAP1, STEAP2) are therapeutic targets in advanced prostate cancer.
  • STEAP expression is linked to androgen receptor (AR) signaling, but regulatory mechanisms and functions in prostate cancer progression are unclear.

Purpose Of The Study

  • To investigate the influence of androgen modulation and AR inhibition on STEAP family member expression in prostate cancer cells.
  • To examine STEAP1 and STEAP2 expression in small extracellular vesicles (sEVs) derived from prostate cancer cells and in circulation.

Main Methods

  • In vitro androgen modulation and AR inhibition experiments on prostate cancer cell lines.
  • Analysis of STEAP family member transcript levels in response to androgen deprivation.
  • Evaluation of STEAP1 and STEAP2 expression in cell-derived and circulating sEVs.
  • Ex vivo analysis of circulating sEVs from genetically engineered mouse models of prostate cancer.

Main Results

  • Androgen deprivation elevated STEAP1 and STEAP2 transcript levels, while reducing STEAP4, mirroring KLK3 expression.
  • STEAP1, but not STEAP2, was upregulated in sEVs from both AR-negative and AR-positive cells.
  • Selective packaging of STEAP1 into sEVs occurred irrespective of cellular STEAP1 levels and AR status.
  • Circulating sEVs in mice with prostate cancer contained STEAP1, independent of prostatic β1 integrin expression.

Conclusions

  • STEAP1 exhibits selective packaging into extracellular vesicles in prostate cancer.
  • STEAP1 levels in circulating sEVs are independent of AR status and β1 integrin expression.
  • Understanding androgen dependence of STEAP1 in tumor cells and sEVs may guide combinatorial therapies.